The development of innovative nucleic acid-based therapies is one of the most promising avenues in current medical research. From vaccines to cancer treatments and gene therapies, lipid nanoparticles (LNPs) play a central role: these tiny lipid carriers are capable of transporting and delivering therapeutic molecules directly into cells. Despite their immense potential, their development remains a lengthy, highly technical and challenging process.

It is to address this challenge that Cayman, a leading authority in lipid research for over 45 years, developed LipidLaunch™. Ready-to-use lipid nanoparticles and reagent kits, designed to simplify the most time-consuming stages of the research process and enable scientists to progress more quickly, without compromising the quality of their results.

With LipidLaunch™, researchers can focus on what truly matters: gaining a deeper understanding of biological mechanisms, identifying new biomarkers and contributing to the development of innovative therapies. As an official distributor of Cayman products, Bertin Bioreagent makes this range available to support the most ambitious research projects.

Science moves forward with the right tools.